Overall Score

Environmental

No material environmental disclosures or controversies were provided in the fresh data.

Capital intensity remains modest, with capex to revenue at 2.4% and capex to operating cash flow at 50.3%, suggesting limited near-term environmental investment pressure.

Social

No material social disclosures or controversies were provided in the fresh data.

R&D spending remains meaningful at 12.6% of revenue, indicating continued investment in product development and patient-related innovation.

Governance

No material governance disclosures or controversies were provided in the fresh data.

Liquidity remains strong with a current ratio of 4.62 and cash per share of 7.89, supporting financial resilience despite weak profitability.